公开(公告)号：US10442814B2

公开(公告)日：2019-10-15

申请号：US15953109

申请日：2018-04-13

Applicant: The University of Liverpool

Inventor： Martin Leuwer ,  Paul M. O'Neill ,  Neil Berry ,  Chandrakala Pidathala

IPC: C07D491/107 ,  C07D205/04 ,  C07D265/30 ,  C07D493/10 ,  C07D295/192 ,  C07D211/06 ,  A61P25/00 ,  A61P23/00

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.

公开(公告)号：US20240108629A1

公开(公告)日：2024-04-04

申请号：US18272697

申请日：2022-01-17

Applicant: Liverpool School of Tropical Medicine ,  The University of Liverpool Foundation Building

Inventor： Joseph D. Turner ,  Weiquan David Hong ,  Paul M. O'Neill ,  Stephen A. Ward ,  Mark J. Taylor

IPC: A61K31/5377 ,  A61K31/519 ,  A61P33/10

CPC classification number: A61K31/5377 ,  A61K31/519 ,  A61P33/10

Abstract: Provided is a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, as defined herein for use in the treatment or prevention of a Dirofilaria infection in a mammal,




The compounds are also for use in the treatment or prevention of diseases or conditions caused by a Dirofilaria infection in a mammal. Also described are corresponding methods of treating or preventing a Dirofilaria infection in a mammal.

公开(公告)号：US11518760B2

公开(公告)日：2022-12-06

申请号：US16478281

申请日：2018-01-17

Applicant: Liverpool School of Tropical Medicine ,  The University of Liverpool ,  Eisai R&D Management Co., Ltd.

Inventor： Stephen A. Ward ,  Mark J. Taylor ,  Paul M. O'Neill ,  Weiqian David Hong ,  Farid Benayoud

IPC: C07D471/04 ,  C07D239/86 ,  C07D495/04

Abstract: The present invention relates to compounds of Formulae (I) and (II) as defined herein, and salts and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formulae (I) and (II), and to the use of compounds of Formulae (I) and (II) in the treatment or prevention of filarial worm infection, as well as other diseases or conditions in which filarial worm infection is implicated.

公开(公告)号：US20190084993A1

公开(公告)日：2019-03-21

申请号：US15953109

申请日：2018-04-13

Applicant: The University of Liverpool

Inventor： Martin Leuwer ,  Paul M. O'Neill ,  Neil Berry ,  Chandrakala Pidathala

IPC: C07D491/107 ,  A61P25/00 ,  A61P23/00 ,  C07D205/04 ,  C07D211/06 ,  C07D493/10 ,  C07D295/192 ,  C07D265/30

Abstract: The present invention relates to compounds of formula I shown below: wherein Q is as defined herein. The compounds of formula I act as selective positive allosteric modulators of strychnine-sensitive alpha 1-glycine receptors. The present invention further relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of diseases or conditions in which strychnine-sensitive alpha 1-glycine receptor activity is implicated (such as, for example, chronic pain. The present invention also relates to processes for the preparation of these compounds and to pharmaceutical compositions comprising them.